osimertinib has been researched along with Anemia--Aplastic* in 2 studies
2 other study(ies) available for osimertinib and Anemia--Aplastic
| Article | Year |
|---|---|
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability.. We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib.. Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it. Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Anemia, Aplastic; Aniline Compounds; Antineoplastic Agents; Humans; Lung Neoplasms; Male; Prognosis | 2020 |
Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
Topics: Acrylamides; Aged; Anemia, Aplastic; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors | 2017 |